

Leptin tA Human, PEG

Description: Pegylated Leptin Antagonist Triple Mutant Human Recombinant is a single non-glycosylated polypeptide chain containing 146 amino and additional Ala at N-terminus acids and having a molecular weight of 35.6kDa, Leptin was mutated, resulting in L39A/D40A/F41A. However due to enlarged hydrodynamic volume it runs on the SDS-PAGE as 48 kDa protein and in gel-filtration on Superdex 200 as over 200 kDa protein. Leptin Antagonist Triple Mutant Human Recombinant is Mono-Pegylated with 20kDa PEG and was purified by proprietary chromatographic techniques.

Catalog #: CYPs-709

For research use only.

Source: Escherichia coli.

Physical Appearance: White lyophilized (freeze-dried) powder.

Purity: Greater than 98.0% as determined by: (a) Gel filtration analysis. (b) Analysis by SDS-PAGE.

Formulation:

The protein was lyophilized from a concentrated (0.65mg/ml) solution with 0.003mM NaHCO₃.

Stability:

Lyophilized PEG-SHLA although stable at room temperature for several weeks, should be stored desiccated below -20°C. Upon reconstitution at > 0.1 mg/ml and up to 2 mg/ml of PEG-SHLA and filter sterilization mLEP mutant can be stored at 4°C or even room temperature for several weeks making it suitable for long term infusion studies using osmotic pumps. At lower concentration addition of a carrier protein (0.1% HSA or BSA) is suggested. Please prevent freeze-thaw cycles.

Usage:

NeoBiolab's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Solubility:

It is recommended to reconstitute the lyophilized Leptin Antagonist Triple Mutant pegylated Human Recombinant in sterile 0.4% NaHCO₃ adjusted to pH 8-9, not less than 100

Biological Activity:

Capable of inhibiting leptin-induced proliferation of BAF/3 cells stably transfected with the long form of human leptin receptor. Its in vitro activity is 6-8 fold lower than the non-pegylated antagonist but in vivo it has profound weight gain effect (as compared to the non-pegylated antagonist), resulting mainly from increased food intake. Its in vivo activity compared to that of PEG-MLA is 9-27 fold higher.

To place an order, please [Click HERE](#).